Home›Caspofungin Acetate

Caspofungin Acetate

Also known as: Cancidas

Route: Intravenous

Check Caspofungin Acetate Interactions →

8 interactions on record

Caspofungin Acetate has 8 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Rifampin, Carbamazepine, Cyclosporine. Patients taking Caspofungin Acetate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 8
Major: 1
Moderate: 7

Major (1)

Caspofungin Acetate + Rifampin— Potent CYP3A4 inducer reduces plasma concentrations of caspofungin acetate. Dose increase to 70 mg daily (adults) or 70 …

Moderate (7)

Caspofungin Acetate + Carbamazepine— Carbamazepine is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased ca…
Caspofungin Acetate + Cyclosporine— Cyclosporine increases AUC of caspofungin acetate. Transient increases in liver ALT and AST occur with concomitant use. …
Caspofungin Acetate + Dexamethasone— Dexamethasone is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased ca…
Caspofungin Acetate + Efavirenz— Efavirenz is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspof…
Caspofungin Acetate + Nevirapine— Nevirapine is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspo…
Caspofungin Acetate + Phenytoin— Phenytoin is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspof…
Caspofungin Acetate + Tacrolimus— Concomitant use with caspofungin acetate requires monitoring. Standard monitoring of tacrolimus trough whole blood conce…

Caspofungin Acetate + Rifampin⚠️Major

Potent CYP3A4 inducer reduces plasma concentrations of caspofungin acetate. Dose increase to 70 mg daily (adults) or 70 mg/m² daily (pediatrics) required.

Caspofungin Acetate + Carbamazepine🟡Moderate

Carbamazepine is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered.

Caspofungin Acetate + Cyclosporine🟡Moderate

Cyclosporine increases AUC of caspofungin acetate. Transient increases in liver ALT and AST occur with concomitant use. Monitor liver enzymes and evaluate risk/benefit.

Caspofungin Acetate + Dexamethasone🟡Moderate

Dexamethasone is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered.

Caspofungin Acetate + Efavirenz🟡Moderate

Efavirenz is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered.

Caspofungin Acetate + Nevirapine🟡Moderate

Nevirapine is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered.

Caspofungin Acetate + Phenytoin🟡Moderate

Phenytoin is a hepatic CYP enzyme inducer expected to reduce caspofungin acetate plasma concentrations. Increased caspofungin dosing should be considered.

Caspofungin Acetate + Tacrolimus🟡Moderate

Concomitant use with caspofungin acetate requires monitoring. Standard monitoring of tacrolimus trough whole blood concentrations and appropriate dosage adjustments are recommended.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.